204 related articles for article (PubMed ID: 16629381)
1. The diversity of RNAi and its applications.
Gaur RK; Rossi JJ
Biotechniques; 2006 Apr; Suppl():4-5. PubMed ID: 16629381
[No Abstract] [Full Text] [Related]
2. Therapeutic potential of RNAi in metabolic diseases.
Rondinone CM
Biotechniques; 2006 Apr; Suppl():31-6. PubMed ID: 16629385
[TBL] [Abstract][Full Text] [Related]
3. RNAi as a treatment for HIV-1 infection.
Rossi JJ
Biotechniques; 2006 Apr; Suppl():25-9. PubMed ID: 16629384
[TBL] [Abstract][Full Text] [Related]
4. RNA interference: a potential therapeutic tool for silencing splice isoforms linked to human diseases.
Gaur RK
Biotechniques; 2006 Apr; Suppl():15-22. PubMed ID: 16629383
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of siRNA-mediated transcriptional gene silencing.
Morris KV
Biotechniques; 2006 Apr; Suppl():7-13. PubMed ID: 16629382
[TBL] [Abstract][Full Text] [Related]
6. Toward silencing the burden of malaria: progress and prospects for RNAi-based approaches.
Brown AE; Catteruccia F
Biotechniques; 2006 Apr; Suppl():38-44. PubMed ID: 16629386
[TBL] [Abstract][Full Text] [Related]
7. Mammalian RNAi: a practical guide.
Sandy P; Ventura A; Jacks T
Biotechniques; 2005 Aug; 39(2):215-24. PubMed ID: 16116795
[TBL] [Abstract][Full Text] [Related]
8. RNAi mechanisms and applications.
Kim D; Rossi J
Biotechniques; 2008 Apr; 44(5):613-6. PubMed ID: 18474035
[TBL] [Abstract][Full Text] [Related]
9. RNA interference: an emerging generation of biologicals.
Shrivastava N; Srivastava A
Biotechnol J; 2008 Mar; 3(3):339-53. PubMed ID: 18320564
[TBL] [Abstract][Full Text] [Related]
10. RNA Therapeutics for Treatment of Cardiovascular Diseases: Promises and Challenges.
Lucas T; Dimmeler S
Circ Res; 2016 Sep; 119(7):794-7. PubMed ID: 27635083
[No Abstract] [Full Text] [Related]
11. Engineering genomics. RNA antagonists--a new class of antisense drugs.
Orum H
IEEE Eng Med Biol Mag; 2005; 24(4):81-7. PubMed ID: 16119218
[No Abstract] [Full Text] [Related]
12. Applications of RNA interference in mammalian systems.
Martin SE; Caplen NJ
Annu Rev Genomics Hum Genet; 2007; 8():81-108. PubMed ID: 17477824
[TBL] [Abstract][Full Text] [Related]
13. Target selectivity in mRNA silencing.
Aronin N
Gene Ther; 2006 Mar; 13(6):509-16. PubMed ID: 16520821
[TBL] [Abstract][Full Text] [Related]
14. RNA-based drugs: from RNA interference to short interfering RNAs.
Poliseno L; Mercatanti A; Citti L; Rainaldi G
Curr Pharm Biotechnol; 2004 Aug; 5(4):361-8. PubMed ID: 15320767
[TBL] [Abstract][Full Text] [Related]
15. Knockdown by RNAi-proceed with caution.
Samuel CE
Nat Biotechnol; 2004 Mar; 22(3):280-2. PubMed ID: 14990947
[No Abstract] [Full Text] [Related]
16. Potentiality of small interfering RNAs (siRNA) as recent therapeutic targets for gene-silencing.
Chakraborty C
Curr Drug Targets; 2007 Mar; 8(3):469-82. PubMed ID: 17348839
[TBL] [Abstract][Full Text] [Related]
17. Gene manipulation through the use of small interfering RNA (siRNA): from in vitro to in vivo applications.
Kumar LD; Clarke AR
Adv Drug Deliv Rev; 2007 Mar; 59(2-3):87-100. PubMed ID: 17434644
[TBL] [Abstract][Full Text] [Related]
18. The potential of oligonucleotides for therapeutic applications.
Fichou Y; Férec C
Trends Biotechnol; 2006 Dec; 24(12):563-70. PubMed ID: 17045686
[TBL] [Abstract][Full Text] [Related]
19. RNA interference in neuroscience: progress and challenges.
Miller VM; Paulson HL; Gonzalez-Alegre P
Cell Mol Neurobiol; 2005 Dec; 25(8):1195-207. PubMed ID: 16388332
[TBL] [Abstract][Full Text] [Related]
20. Oncogene dependency and the potential of targeted RNAi-based anti-cancer therapy.
Yan R; Hallam A; Stockley PG; Boyes J
Biochem J; 2014 Jul; 461(1):1-13. PubMed ID: 24927119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
